Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi).
Go to Source
https://medicalxpress.com/rss-feed/
Go to Source
https://medicalxpress.com/rss-feed/